Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Emergex Vaccines Holding Ltd
Emergex Vaccines Holding Ltd
Activities:
Pharmaceutical
X
LinkedIn
Trending Articles
Optimising RNA production for faster and cheaper pharmaceutical manufacturing
RNA production can be a lengthy and complex process, but the Ntensify platform could change this by diminishing development times, decreasing production costs and allowing the...
ChargePoint invest in a single-use manufacturing facility to expand product line
The single-use manufacturing facility will become fully operational in June 2024, and will support the company's trio of liquid and powder transfer devices
Memel Biotech and Therabest collaborate to develop exosome-based cell therapies
The partnership will aim to develop, manufacture and distribute novel exosome cell therapies in a range of therapeutic areas
Owlstone Medical bags $6.5m to optimise infectious disease diagnostic tool
The Bill & Melinda Gates Foundation has funded the bolstering of the Breath Biopsy platform, as well as research into breath biomarkers in tuberculosis (TB) and HIV
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Recruitment
Dr Athanasios Papadopoulos joins Emergex as Chief Medical Officer
Oxford-based biotechnology company has appointed a clinical bio-pathology specialist
Research & Development
Emergex secures R&D facility in Oxfordshire
English biotech company now has overall internal control of all its vaccine development programmes
Infection Control
Emergex to develop novel vaccines against viral diseases
The biotech will collaborate with the Oswaldo Cruz Foundation to develop the vaccines
Pharmaceutical
Emergex files patent in US for novel pandemic flu vaccine
The patent, ‘Reverse Peptide Vaccines’, covers the use of peptides derived from human influenza A
Manufacturing
Emergex receives Innovate UK Grant to progress flu vaccine
The biotechnology company, which is aiming to find a new approach to vaccine development, has received a grant to progress its development programme
Recruitment
Emergex Vaccines appoints new member to board of directors
Recruitment
Emergex builds its Finance Team with two new recruits
Subscribe now